64 followers
Results from:phase III EMPEROR-Preserved trial,were published in The New England Journal of Medicine in 2021. In the double blind trial’s HFpEF patients,the #SGLT2_i empagliflozin led to around21% lower relative risk of CV deaths &HF hospitalization. h